[ET Net News Agency, 3 September 2021] CSPC Pharmaceutical Group Limited (01093) said
Shanghai Novarock Biopharmaceutical Co., Ltd., a subsidiary of the company, has obtained
approval granted by the National Medical Products Administration of the People's Republic
of China to conduct clinical trial for NBL-015 in China.
NBL-015 is a fully human anti-Claudin 18.2 monoclonal antibody discovered and developed
by NovaRock Biotherapeutics Limited, a subsidiary of the company, for treating advanced
solid tumours with positive Claudin 18.2 expression, including pancreatic cancer and
gastric cancer (including cancer of the gastroesophageal junction). The Phase I clinical
trials will evaluate the safety, tolerability and pharmacokinetics of NBL-015 in patients
with advanced solid tumours. (RC)